The information provided on this page is for reference only. Please refer to the latest information published by the partner company.
We truly believe that ACT Genomics can change the existing cancer treatment model and make cancer manageable. To enable patients and their families to fight cancer with dignity, our precise comprehensive cancer management facilitates treatment with higher efficiency and accuracy.
ACTOnco® + comprehensive genomic profiling, ACT Genomics’ flagship panel, is developed with the aim of supporting and answering the clinical challenges faced during the management of major solid tumors, including carcinomas, sarcomas, and lymphomas. The ACTOnco® + panel comprises 440 specially-curated genes, 31 fusion genes and 182 fusion transcripts。 It references the Hallmarks of Cancer to facilitate treatment strategies, including: Chemotherapy, Targeted therapy, Immunotherapy and Pharmacogenomics.
ACTOnco® +covers tumor mutational burden(TMB), microsatellite instability(MSI) status and immune - related genes to provide a more accurate prediction of ICI responses.It comprehensively identifies genetic alterations of each signaling pathway to evaluate drug options based on upstream and downstream interactions.By incorporating comprehensive genomics profiling and integrating signaling pathway analysis, ACTOnco® +provides clinicians with a more holistic understanding of the major cancer - driven events during tumorigenesis and provides more targeted therapeutic strategies.
Hong Kong Science Park is the centre of technology and research in Hong Kong. It is a vibrant and energetic community of innovation. With excellent infrastructure, state-of-the-art laboratories and a strong platform, it provides the ideal environment for innovative businesses and entrepreneurs to excel.
HKSTP also assists us in connecting with relevant industries and investors for business expansion.